Are anti-androgens can COMBINATION Tacrolimus FK-506 with prior brachytherapy in an effort to reduce the volume of the prostate and minimize m Possible adverse effects associated with brachytherapy, used as a symptom My urine in patients with big he prostate. In one study, patients with T1b prostate cancer T2c was new U 3 6 months, a GnRH agonist prior to brachytherapy. The mean decrease in prostate volume with ADT was 33% among the 54 evaluable patients. That this approach leads to improved contr The tumor is too long determined.26 In another study in patients with prostate cancer have bulky again U 3 months before the CAB and the final RT median percentage reduction of the target volume was 25% after CAB. This approach was used on the geometry of the target volume in relation to adjacent normal tissue structures before RT.27 optimization of hormone therapy, however, about the size E of the prostate for external beam radiotherapy to reduce RT more widespread. The addition of ADT to prime Ren external beam RT for localized prostate cancer is clinically well defined patients with the disease intermediateand high risk for a number of controlled studies Randomized strips. A randomized study was conducted in elementary school, with or without RT in patients 6 months of ADT for prostate cancer with T1b T2b disease, a Gleason score ofo7, evidence extrakapsul Re extension or an installment PSA ofo10 ng ML21. Most patients in this study, often referred to as the Dana Farber or D MICO study had an average risk of disease, with approximately 15% at high risk. Patients randomized to the combination arm had a significantly h Here survival rate, lower mortality from prostate cancer-specific survival, and h Here ADT recovery without a median follow-up of 4.5 years.28 The Radiation Therapy Oncology Group study, 94 08 evaluated a shorter duration ADT in patients with T1b T2b disease and a PSA off20 ML21 ng. The addition of 4 months of ADT 2 months before RT was associated with improved OS by 62% at 10 years of treatment compared to 57% for those with RT alone. In a post hoc subgroup analysis, the benefit for patients with intermediate risk, no risk low ones.29 The optimal timing of ADT with RT was seen in prostate cancer has been studied clinically localized in the RTOG 9413 trial. The trial of four arms was designed to test two hypotheses: CAB wholepelvic and radiotherapy followed by an increase in prostate improves progression-free survival of o10% of the cabin and prostate as RT, and followed neoadjuvant hormonal therapy with concomitant CAB and improve the progression-free survival by RT o10% compared to RT, followed by adjuvant hormonal therapy. There was no difference in PFS between the arms of neoadjuvant and adjuvant. An unexpected interaction was found between the time of hormone therapy and radiation Feldgr E Bendamustine for this patient group. If neoadjuvant hormonal therapy was used in conjunction with RT, WPRT was better than PFS prostate RT, and additionally Tzlich, hormonal therapy, neoadjuvant more WPRT led to a better use of adjuvant hormone therapy.30 closing Lich WPRT, in a phase III study in Canada, that randomized patients with prostate cancer clinically to 3 months before 8 months of ADT before definitive RT combined is localized, whereas no difference was observed between.